NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · Real-Time Price · USD
1.100
+0.020 (1.85%)
Nov 13, 2025, 4:00 PM EST - Market closed
Company Description
NovaBay Pharmaceuticals, Inc. does not have significant operations.
Previously, the company was engaged in the development and sale of eyecare, wound care, and skin care products in the United States and internationally.
The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007.
NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
NovaBay Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2000 |
| IPO Date | Oct 26, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Michael Kazley |
Contact Details
Address: 2000 Powell Street, Suite 1150, eleventh floor Emeryville, California 94608 United States | |
| Phone | 510 899 8800 |
| Website | novabay.com |
Stock Details
| Ticker Symbol | NBY |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001389545 |
| CUSIP Number | 66987P201 |
| ISIN Number | US66987P4090 |
| Employer ID | 68-0454536 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Tommy Law | Controller, Interim Chief Financial Officer and Treasurer |
| Justin M. Hall Esq., J.D. | Vice President of Business Dev., General Counsel, Chief Compliance Officer, Corporate Secretary and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 7, 2025 | 10-Q | Quarterly Report |
| Oct 22, 2025 | 8-K | Current Report |
| Oct 21, 2025 | 8-K | Current Report |
| Oct 20, 2025 | SCHEDULE 13D/A | Filing |
| Oct 20, 2025 | SCHEDULE 13D/A | Filing |
| Oct 20, 2025 | 8-K | Current Report |
| Oct 17, 2025 | SCHEDULE 13D/A | Filing |
| Oct 17, 2025 | SCHEDULE 13D/A | Filing |
| Oct 15, 2025 | SCHEDULE 13D | Filing |
| Oct 15, 2025 | SCHEDULE 13D | Filing |